*REPLAY* KOL Discussion on TMS, Spravato, Psychedelics: LFST, CMPS, DFTX, ATAI

Research evidence excerpt

*REPLAY* KOL Discussion on TMS, Spravato, Psychedelics: LFST, CMPS, DFTX, ATAI

Expert

Series

USA | Health Care Facilities EquityJuneResearch17, 2026

*REPLAY* KOL Discussion on TMS, Spravato,

Psychedelics: LFST, CMPS, DFTX, ATAI

We hosted a discussion with Interventional Psychiatrist Dr. Alik Widge

(University of Minnesota) and discussed: (1) Current interventional psychiatry

treatments for depression (e.g., TMS, Spravato), (2) key themes driving demand .

growth, (3) reimbursement and unit economics, and (4) the anticipated

adoption and commercial dynamics of novel psychedelics (e.g., CMPS, DFTX,

ATAI, HELP). See replay HERE.

**See replay link HERE**

Jefferies Hosts

First Half: Jack Slevin (US Healthcare Services) - jslevin@jefferies.com•

Second Half: Andrew Tsai (US Biotechnology) - atsai@jefferies.com•

Speaker Biography

Dr. Alik Widge brings deep expertise in both established and emerging neurostimulation

technologies, with a focus on advancing brain stimulation and neural interface solutions for

psychiatric care. His work centers on developing next-generation therapies across a range of

conditions, including depression, OCD, PTSD, anxiety, addiction, and autism. He has served as a

principal investigator on multiple clinical trials for invasive neurostimulation therapies, while also

training physicians in the clinical application of deep brain stimulation.

Interventional Psychiatrist and Biomedical Engineer•

Professor at the University of Minnesota (09-2018 -- Present)•

Assistant Professor of Psychiatry at Harvard Medical School (03/2016 -- 01/2018)•

Instructor in Psychiatry at Harvard Medical School (06/2014 -- 03/2016)•

Jack Slevin, CFA * | Equity Analyst

+1 (212) 284-4686 | jslevin@jefferies.com

Andrew Tsai * | Equity Analyst

+1 (415) 229-1566 | atsai@jefferies.com